McGovern Medical School

Innosphere launches non-pharmaceutical ADHD clinical trial at top-tier research hospitals seeking pediatric patients

Retrieved on: 
Thursday, May 2, 2024
FDA, McGovern Medical School, Patient, Brain, Mayo Clinic, Hospital, Safety, MD, Doctor of Philosophy, Bentham Science Publishers, ADHD, White noise, Aggression, Attention, Psychiatry, Baylor College of Medicine, Headache, Texas Children's Hospital, Boston Children's Hospital, Clinical trial, Engineering

BERLIN, May 2, 2024 /PRNewswire/ - Innosphere Engineering Ltd (Innosphere or the Company), a medical device company developing non-pharmaceutical treatments for ADHD, is pleased to announce the launch of recruitment for a randomized, sham-controlled, double-blind clinical trial examining the safety and effectiveness of Novostim 2 transcranial Random Noise Stimulation (tRNS) on ADHD symptoms in pediatric patients (7 – 12 years).

Key Points: 
  • BERLIN, May 2, 2024 /PRNewswire/ - Innosphere Engineering Ltd (Innosphere or the Company), a medical device company developing non-pharmaceutical treatments for ADHD, is pleased to announce the launch of recruitment for a randomized, sham-controlled, double-blind clinical trial examining the safety and effectiveness of Novostim 2 transcranial Random Noise Stimulation (tRNS) on ADHD symptoms in pediatric patients (7 – 12 years).
  • 2016 data from the Centers for Disease Control and Prevention estimates 6 million children had been given diagnoses of ADHD and 62 percent were taking medication, often stimulants.
  • "Pharmaceuticals and specifically stimulants have been the standard of care in ADHD for decades, with challenging side effects well documented," says Rami Shacour, co-Founder and CEO of Innosphere.
  • "Building on our previous successful clinical trial , we are ecstatic to provide a non-medicated option for children in need and look forward to a swift and impactful trial."

Experts to examine how Supreme Court Affirmative Action decision impacts legal and medical education at upcoming University of Houston event

Retrieved on: 
Wednesday, April 3, 2024
Constitution, Internal medicine, Tilman, Professional development, SFFA, University, Harvard University, Nature, Associate professor, DEI, Inclusion, Equal Protection Clause, Dean (education), University college, Family medicine, Virginia School for Girls, Diversity, Environmental studies, Law School Admission Council, Supreme court, Operation, MPP, University of Houston, MCLE, College of Medicine, Associate, Community health, Student, Community engagement, Supreme, Law Center, Medical school, McGovern Medical School, Psychiatry, Assistant, Behavioural sciences, LSAC, Baylor College of Medicine, CME, Management

"In SFFA v. Harvard, the U.S. Supreme Court found that the race-conscious admission policies of Harvard University and the University of North Carolina violated the Equal Protection Clause of the U.S. Constitution," said UH Law Center Dean Leonard Baynes.

Key Points: 
  • "In SFFA v. Harvard, the U.S. Supreme Court found that the race-conscious admission policies of Harvard University and the University of North Carolina violated the Equal Protection Clause of the U.S. Constitution," said UH Law Center Dean Leonard Baynes.
  • "The Supreme Court decisions on affirmative action have reshaped the landscape at medical schools across the country," said Dr. Stephen Spann, founding dean of the Fertitta Family College of Medicine.
  • "It is important to understand the impacts, so our students continue receiving the best health care education and our clinicians continue providing quality health care services to the community."
  • Attending healthcare and legal professionals will earn 6 hours of Texas MCLE credit or 6.25 CME credits, respectively.

Aruna BIO Establishes Stroke Advisory Board to Advance Lead Program, AB126 into the Clinic

Retrieved on: 
Monday, March 4, 2024
University of Texas System, Bangladesh Technical Education Board, School, Boston Medical Center, Dementia, NIH, University, Cerebrovascular disease, SAB, Stroke, Frank, Radiology, History, Biomedical sciences, Clinical, UNC, Clinical trial, Knowledge, McGovern Medical School, Pediatrics, Research, BMC, Pharmaceutical industry

BOSTON and ATHENS, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative diseases, is pleased to announce the formation of its Stroke Advisory Board (SAB). Comprising distinguished experts in fields of neurology, stroke research, and clinical development, the board underscores Aruna Bio’s commitment to advancing its clinical development program with unparalleled expertise.

Key Points: 
  • Comprising distinguished experts in fields of neurology, stroke research, and clinical development, the board underscores Aruna Bio’s commitment to advancing its clinical development program with unparalleled expertise.
  • The newly established board features renowned figures in the medical and scientific community, each bringing a wealth of knowledge and experience to Aruna Bio.
  • “AB126 is making history with the first exosome therapy to enter human clinical trials for a neurological condition,” said Stephen From, Chief Executive Officer at Aruna Bio.
  • “This represents a significant step forward in our quest to transform the treatment landscape for stroke and other neurodegenerative diseases.

Viz.ai Announces Six Clinical Studies that Further Validate Impact of Viz™ Neuro Suite on Patient Care

Retrieved on: 
Wednesday, February 7, 2024
Software, Research, General Health, Technology, Medical Devices, Infectious Diseases, Hospitals, Artificial Intelligence, Health Technology, Clinical Trials, Science, Neurology, Health, Shift, CNN, Conference, ISC, Atrial fibrillation, DTG, Neurosurgery, Workflow, FAHA, Diagnosis, ICM, Aneurysm, Intraparenchymal hemorrhage, AI, MLS, Automation, MD, Single Center, Abstract (summary), Stroke, Viz, ICH, Patient, Groin, Triage, Intervention, Artificial intelligence, CSC, UIA, Intracranial hemorrhage, Associate, University of Kentucky, University, McGovern Medical School, Ambient occlusion, Medical device

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in neurovascular care.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in neurovascular care.
  • “As a leader in AI-powered stroke detection and care coordination, Viz.ai does not rest on what we have done, but instead continues to invest in proving the accuracy and impact of our comprehensive Viz Neuro Suite,” said Molly Madziva Taitt, VP, Global Clinical Affairs.
  • This study is the first of its kind to assess the impact of AI in the acute stroke workflow based on user engagement.
  • For more information on the Viz Neuro Suite, visit https://www.viz.ai/neuro .

ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX

Retrieved on: 
Wednesday, January 24, 2024
Obesity, Patient, FLEX, Weight loss, Food, University, Division, NYU, McGovern Medical School, Bariatric surgery, FDA, Physician, Surgeon, Medical device

“Training surgical fellows on our Lap-Band® System provided ReShape the opportunity to introduce the next generation of bariatric surgeons to our FDA approved, minimally invasive, long-term treatment for obesity," stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences.

Key Points: 
  • “Training surgical fellows on our Lap-Band® System provided ReShape the opportunity to introduce the next generation of bariatric surgeons to our FDA approved, minimally invasive, long-term treatment for obesity," stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences.
  • Similar to our existing Lap-Band®, the Lap-Band® 2.0 FLEX technology acts as a relief valve, allowing larger pieces of food to more easily pass through the narrowed passage (or stoma), created by the band.
  • “The unique insights I have learned from performing minimally invasive Lap-Band® procedures on my patients were the impetus for organizing the training of this emerging group of bariatric surgeons.
  • Lap-Band® 2.0 FLEX will potentially remedy this issue because of the ability for self-correction utilizing an internal reservoir system.”

American College of Lifestyle Medicine announces 2023 Dr. Stephen Turner Residency Director and Faculty Scholarship recipients

Retrieved on: 
Tuesday, October 17, 2023
Linda, Type 2 diabetes, Health, Certification, ACLM, Knowledge, PT, Mayo Clinic, Physician, Internal medicine, The Oregon Trail 4th Edition, Student, The Wall Street Journal, Faculty, Obesity, LM, American College, Prevalence, Curriculum, MPH, LMRC, Sports medicine, Future, Conditional sentence, Medicine, American Board of Commissioners for Foreign Missions, Patient, Workforce, Rehabilitation, Doctor of Public Health, McGovern Medical School, Molina Healthcare, Lifestyle medicine, Pharmaceutical industry, Nursing, Dentistry, Dietary supplement, RD, MD

ST. LOUIS, Oct. 17, 2023 /PRNewswire-PRWeb/ -- The American College of Lifestyle Medicine (ACLM) and American Board of Lifestyle Medicine (ABLM) have announced the 14 recipients of the 2023 Dr. Stephen Turner Residency Director & Faculty Scholarship supporting the integration of lifestyle medicine into residency programs across the country.

Key Points: 
  • The scholarships support certification in lifestyle medicine for residency program directors and faculty members interested in integrating lifestyle medicine into their residency programs.
  • ST. LOUIS, Oct. 17, 2023 /PRNewswire-PRWeb/ -- The American College of Lifestyle Medicine (ACLM) and American Board of Lifestyle Medicine (ABLM) have announced the 14 recipients of the 2023 Dr. Stephen Turner Residency Director & Faculty Scholarship supporting the integration of lifestyle medicine into residency programs across the country.
  • The scholarships cover the full cost of certification in lifestyle medicine to equip residency program directors and faculty with the confidence, knowledge and skills to implement the Lifestyle Medicine Residency Curriculum (LMRC) and train residents in their program.
  • This year's scholarship recipients come from 11 states and represent residency specialties that include family medicine, internal medicine, sports medicine, preventive medicine, pediatric medicine and physical medicine and rehabilitation.

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11

Retrieved on: 
Friday, October 6, 2023
Irritant, Parent, Food, Doctor of Philosophy, Propylene glycol, Shanda, Silver, Caregiver, JD, Safety, Psoriasis, Disease, MUSE, FAAD, FDA, National Psoriasis Foundation, McGovern Medical School, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Skin, Child, Ethanol, Dermatology, Face, Excipient, Quality of life, Dietary supplement, Pharmaceutical industry, MD

ZORYVE, a once-daily, steroid-free cream that is effective, safe, and well tolerated, is designed to simplify management of plaque psoriasis.

Key Points: 
  • ZORYVE, a once-daily, steroid-free cream that is effective, safe, and well tolerated, is designed to simplify management of plaque psoriasis.
  • “ZORYVE has been shown to be safe, well tolerated, and effective; all critical factors for treating children with plaque psoriasis.
  • Plaques in sensitive areas, where the skin may be thinner or more sensitive, pose specific treatment challenges.
  • “In children, psoriasis ranges from mild to severe, and more often appears on sensitive areas including the face and skin folds, compared to adults.

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease

Retrieved on: 
Monday, August 28, 2023
Huntington's disease, Pit additive, KINECT, Lancet Neurology, Week, Disease, McGovern Medical School, Neurocrine Biosciences, Clinical Global Impression, Movement disorder, The Lancet, MDS, Capsule, Movement, TMC, SAN, Chorea, Parkinson's disease, FANA, Neurology, Poster, FAAN, FDA, Safety, Pharmaceutical industry, HD

SAN DIEGO, Aug. 28, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data on now FDA-approved INGREZZA® (valbenazine) capsules for the treatment of adults with chorea associated with Huntington's disease (HD), including exploratory results from the Phase 3 KINECT®-HD study, which showed consistently greater improvements in HD chorea with INGREZZA versus placebo from Week 2 to Week 12. These data will be presented at the MDS International Congress of Parkinson's Disease and Movement Disorders®August 27-31 in Copenhagen, Denmark.

Key Points: 
  • These data will be presented at the MDS International Congress of Parkinson's Disease and Movement Disorders®August 27-31 in Copenhagen, Denmark.
  • "The exploratory analysis from our KINECT-HD study further exemplifies the value of INGREZZA as a now approved medication for HD chorea with improvements seen with treatment as early as two weeks," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences.
  • "This exploratory analysis has increased our insight regarding the early and sustained improvements in chorea severity."
  • Additional HD chorea presentations at the MDS International Congress of Parkinson's Disease and Movement Disorders include:

Neurocrine Biosciences Announces FDA Approval of INGREZZA® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease

Retrieved on: 
Friday, August 18, 2023
Huntington's disease, Maintenance, VMAT2, Chorea, Depression, Pharmacy, Somnolence, Disease, Huntington's Disease Society of America, Neurocrine Biosciences, Quality of life, Medicine, NMS, Hives, Behavior, Rash, HSG, Insomnia, Capsule, LSM, TMC, Patient, McGovern Medical School, Neuroleptic malignant syndrome, SAN, FANA, Suicidal ideation, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FAAN, Food, Caregiver, Safety, Pharmaceutical industry, Birth control, HD, Neurology

"We are thankful for those in the HD community who helped contribute to this important milestone, and we remain committed to bringing medicines to patients with unmet medical needs for debilitating neurological disorders."

Key Points: 
  • "We are thankful for those in the HD community who helped contribute to this important milestone, and we remain committed to bringing medicines to patients with unmet medical needs for debilitating neurological disorders."
  • In clinical studies in Huntington's disease, treatment-emergent adverse events included somnolence and sedation, urticaria, rash and insomnia.
  • "Data also demonstrated INGREZZA was generally well tolerated and showed clinically meaningful improvement in adults with chorea associated with HD."
  • "The approval of INGREZZA for HD chorea means that people living with HD have a new treatment option to help manage their chorea symptoms, which is a welcomed milestone in efforts to improve care for families affected by HD."

University of Phoenix College of Doctoral Studies releases white paper exploring burnout as a cause for job dissatisfaction

Retrieved on: 
Saturday, August 12, 2023
Professional Services, Education, Business, Other Professional Services, Human Resources, University, Training, Burnout, Health administration, Emergency medicine, University of Texas System, DHA, Causality, Child protective services, Workplace, Teaching, McGovern Medical School, Marriage, Psychotherapy, MBA, Job satisfaction, Great Lakes University of Kisumu, Argosy University, University of Phoenix, Organization, Interface (computing), Business administration, Student, City, Tuberculosis, Doctor, Child, Barstow Community College, Phoenix College, University of Texas Health Science Center at Houston, Master of Business Administration, Health, Mental health, Nursing

University of Phoenix College of Doctoral Studies has released a new white paper, “Burnout as a Cause for Job Dissatisfaction,” a collaboration between authors Christa Banton, Ed.D., fellow in the University’s Center for Workplace Diversity and Inclusion Research (CWDIR) and Jose Garza, DHA, MBA, fellow, CWDIR.

Key Points: 
  • University of Phoenix College of Doctoral Studies has released a new white paper, “Burnout as a Cause for Job Dissatisfaction,” a collaboration between authors Christa Banton, Ed.D., fellow in the University’s Center for Workplace Diversity and Inclusion Research (CWDIR) and Jose Garza, DHA, MBA, fellow, CWDIR.
  • The white paper proposes that to address burnout, it is imperative to understand the facets of job satisfaction and create solutions to improve job satisfaction and overall burnout.
  • “Understanding the consequences of job dissatisfaction and tracking an organization’s level of work-life balance can provide an early indicator of intervention to improve job satisfaction, retention rates, and decrease overall burnout,” states Banton.
  • Garza completed his Doctorate in Health Administration with University of Phoenix and a Master of Business Administration with a concentration in healthcare management from Our Lady of the Lake University.